Commitments and Contingencies	6 Months Ended
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company's commitments, including significant license agreements, are disclosed in Note 10 Commitments and Contingencies in the audited financial statements for the year ended December 31, 2024, and notes thereto, included in the Annual Report. Since the date of those financial statements, there have been no material changes to its commitments, other than as noted below. Reduction in Force On April 29, 2025, the Company's board of directors approved a strategic plan, designed to increase the focus of the Company’s resources on its expanding portfolio of clinical candidates in Duchenne muscular dystrophy (“DMD”) and key preclinical programs. In connection with the new strategic plan, the Company reduced its workforce by approximately 20% (the "Reduction"). The Reduction was substantially completed during the second quarter of 2025. As a result of the Reduction, the Company incurred a total charge of $1.9 million, primarily consisting of one-time severance payments and employee termination-related benefits, during the three months ended June 30, 2025. $1.7 million of the charge was recorded as research and development expenses and $0.2 million of the charge was recorded as general and administrative expenses. The Company does not expect to incur additional charges related to the Reduction. As of June 30, 2025, $1.6 million of the costs associated with the Reduction were paid and the remaining $0.3 million were accrued for and recorded in accrued expenses and other current liabilities.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

The Company's commitments, including significant license agreements, are disclosed in Note 10 Commitments and Contingencies in the audited financial statements for the year ended December 31, 2024, and notes thereto, included in the Annual Report. Since the date of those financial statements, there have been no material changes to its commitments, other than as noted below.

Reduction in Force

On April 29, 2025, the Company's board of directors approved a strategic plan, designed to increase the focus of the Company’s resources on its expanding portfolio of clinical candidates in Duchenne muscular dystrophy (“DMD”) and key preclinical programs. In connection with the new strategic plan, the Company reduced its workforce by approximately 20% (the "Reduction"). The Reduction was substantially completed during the second quarter of 2025.

As a result of the Reduction, the Company incurred a total charge of $1.9 million, primarily consisting of one-time severance payments and employee termination-related benefits, during the three months ended June 30, 2025. $1.7 million of the charge was recorded as research and development expenses and $0.2 million of the charge was recorded as general and administrative expenses. The Company does not expect to incur additional charges related to the Reduction. As of June 30, 2025, $1.6 million of the costs associated with the Reduction were paid and the remaining $0.3 million were accrued for and recorded in accrued expenses and other current liabilities.